Genkyotex Appoints Elias Papatheodorou as Chief Business Officer

GENEVA & ARCHAMPS, France--(BUSINESS WIRE)--Genkyotex, the leading developer of selective NOX inhibitors, today announced the appointment of Elias Papatheodorou to the position of Chief Business Officer. A seasoned executive, Mr. Papatheodorou brings to Genkyotex more than 20 years of experience with international private and public biotechnology companies, most recently at Covagen AG.

"Elias has an impressive track record in business development and licensing transactions. He will play a key role in leveraging the promise of our NOX inhibitor franchise."
"Genkyotex has built a strong position in developing first-in-class NOX inhibitors and our most advanced compounds targeting diabetic nephropathy, and fibrotic and inflammatory diseases represent only the beginning. Our leadership in this area of drug development presents a breadth of opportunity for further corporate growth," said Dr. Ursula Ney, CEO of Genkyotex. "Elias has an impressive track record in business development and licensing transactions. He will play a key role in leveraging the promise of our NOX inhibitor franchise."

As Chief Business Officer of Covagen AG, Mr. Papatheodorou was instrumental in securing the sale of Covagen to Janssen Pharmaceuticals, a Johnson & Johnson Company. Previously Mr. Papatheodorou held various roles at Medigene AG, novosom AG, and ATI Medical Imaging and has been responsible for negotiating many licensing and asset deals with major pharmaceutical companies. Mr. Papatheodorou received his undergraduate education at Ithaca College and his graduate education at Cornell University.

Further biographical details on Mr. Papatheodorou can be found at: http://www.genkyotex.com/genkyotex/index.cfm/company/management-team/elias-papatheodorou/.

About Genkyotex

Genkyotex is unlocking the potential of selective NOX enzyme inhibition to discover and develop a pipeline of drugs for hard to treat chronic diseases. NOX enzymes oxidize proteins, activating multiple disease pathways. Our first-in-class NOX inhibitors block this process to achieve broad therapeutic benefit in a range of prevalent and orphan diseases.

For further information please visit www.genkyotex.com

Suggested Articles

When thinking about clinical research patient recruitment, a crucial step is building effective patient recruitment advertising campaigns.

Novavax delayed the start of a large phase 3 trial for its COVID-19 vaccine in the U.S. and Mexico, thanks to delays in scaling up manufacturing.

The decision to dump IL33r antagonist GSK3772847 follows lackluster clinical data on rival candidates against the same target.